How to 投資する in the Ozempic 負わせる loss にわか景気 - and pile on the 続けざまに猛撃するs: MIDAS SPECIAL
Millions of people are 注入するing themselves with 負わせる loss 麻薬s and the 会社／堅いs that make them have seen their 株 prices 急に上がる.
But can 投資家s still 利益（をあげる） now if they buy into companies like Ozempic-製造者 Novo Nordisk? Our Midas 株 Tips 在庫／株 選ぶing 専門家 Joanne Hart takes a look and 暴露するs other ways 投資家s could play the 負わせる loss にわか景気.
Owner of X, 以前 Twitter, Elon Musk has 認める using Wegovy to lose 負わせる?
My cousin Susie 戦う／戦いd with her 負わせる for years. And it was a 堅い 戦う／戦い. There was the 取調べ／厳しく尋問するd meat and citrus fruit diet, the cashew nut and pineapple diet, the cottage cheese and not much else diet.?
There was juicing, 負わせる 選挙立会人s, no fat, 十分な fat, no breakfast, big breakfast.?
You 指名する it, she tried it. The 負わせる （機の）カム off. But, each time she stopped dieting, the 続けざまに猛撃するs p iled 支援する on.?
Then her doctor 定める／命ずるd a daily 注射 of something called Saxenda.?
Suddenly, Susie stopped feeling hungry, stopped feeling breathless and started feeling good.
Susie is not alone. Millions of people are now 注入するing themselves with 負わせる loss 麻薬s, either 公式に, after 捜し出すing 医療の advice, or 非公式に, after seeing celebrities and social マスコミ influencers wax lyrical about their 影響s.
The market is 抱擁する, with some 分析家s 示唆するing it will be 価値（がある） more than £100 billion a year within the next １０年間.
Today, that market is 支配するd by Novo Nordisk, a Danish 麻薬s group 設立するd 100 years ago and based just outside Copenhagen.?
Not only did Novo Nordisk invent Saxenda, it also makes Wegovy, known as the Viagra of the 負わせる loss world, and Ozempic, 初めは designed to 扱う／治療する?糖尿病?but now 広範囲にわたって used by 食餌療法している人s, too.?
Together, these three 麻薬s have helped to make Novo the largest 名簿（に載せる）／表（にあげる）d 商売／仕事 in Europe, valued at almost £350 billion.
Six-倍の 株 price growth but be careful?
Five years ago, Novo Nordisk 株 were 160 Danish krone (£18.43) apiece. They have risen almost sixfold since then, to 903 krone (£103), and many 信奉者s believe the 在庫／株 could become weightier still.?
によれば the?World Health Organisation, almost a billion adults are clinically obese, with another 1.5 billion 分類するd as overweight, more than 40 per cent of the 18-加える 全住民.
The numbers have 二塁打d in the past 30 years, they show few 調印するs of slowing 負かす／撃墜する and are worse in the UK, where more than 60 per cent of adults are tubbier than doctors would like. That 示唆するs there are plenty of cus tomers for 負わせる loss? 麻薬s.
This month, Novo Nordisk 明らかにする／漏らすd that at least 25,000 new 患者s are 調印 up for Wegovy every week in America and 供給（する）s are running short.
Former X-Factor 裁判官 Sharon Osbourne has also 是認するd the 負わせる loss jab Wegevy?
需要・要求する is likely to 急に上がる even その上の as Novo's 負わせる loss 麻薬s are 公式に 認可するd in more markets, more doctors 定める／命ずる them and exciting, new 利益s are discovered from the Danish 大臣の地位.
Last week, results from a major 裁判，公判 示すd that the 重要な 成分 in Ozempic and Wegovy ? semaglutide ? could 削除する the 危険 of heart attacks and 一打／打撃s by 20 per cent.
Cardiologists 述べるd the 熟考する／考慮する as groundbreaking, while some 専門家s think the 麻薬s could work against other 条件s too, such as Parkinson's and 腎臓 病気.
With 人物／姿／数字s 急に上がるing, 需要・要求する 増加するing and social マスコミ going wild over Wegovy, it seems as if Novo Nordisk can do no wrong.?
But even if 投資家s feel like grabbing a slice of the 活動／戦闘, they should be 手段d in their approach to this 在庫／株.
Beware those celebrity 裏書，是認s?
For a start, while celebrities from Sharon Osbourne to Jeremy Clarkson have 賞賛するd Wegovy, others are not so sure.?
Stephen Fry （機の）カム off Ozempic after 説 the 麻薬 made him vomit and many 使用者s complain of nausea, constipation or runny tummy from the fat jabs. Others moan that they look older and some even 示唆する that their 底（に届く）s become saggy after a period of 注射s!
Even those who experience no 味方する-影響s can find it strange to lose all their enjoyment of food or drink.?
Most 意味ありげに, perhaps, it is 不明瞭な whether 使用者s ke ep their 負わせる off once they stop using the 麻薬s and it is too 早期に to tell whether there are any 味方する-影響s from 長引かせるd use.
obbie Williams has 認める taking an Ozempic-style 麻薬 but has not 明らかにするd which
US 巨大（な） Eli Lilly is hot on Novo Nordisk's heels.
Nonetheless, semaglutide has been あられ／賞賛するd as a 奇蹟 cure, 特に for those who are 本気で overweight and at 危険 of 関係のある 病気s. Not surprisingly, therefore, 競争相手s are racing to jump on the bandwagon, with US 麻薬s 巨大（な）, Eli Lilly galloping into second place.
Like Novo, Eli Lilly has a long history of making diabetic 麻薬s and has now pivoted to the 負わせる loss market.?
Diabetic jab Mounjaro has been repurposed as Zepbound, both 麻薬s have been 飛行機で行くing off the 棚上げにするs and Eli Lilly's 株 have followed 控訴, 急に上がるing more than 35 per cent to $770 (£606) since regulators in the US gave its 負わせる loss 治療s the thumbs-up last November.
The 商売／仕事 based in Indianapolis, Indiana, has plenty of 支持者s, too, who believe its 株 price should fatten up, particular after some 熟考する／考慮するs 示唆するd that its jabs are even more 効果的な than the Danish trio.
No one 疑問s, however, that both Novo Nordisk and Eli Lilly are changing the 負わせる loss game and both are struggling to keep up with 需要・要求する, にもかかわらず exorbitant costs.?
Ozempic and Zepbound sell for around $1,000 (£790) a month while Wegovy is on sale for more than $1,300 (£1,030) a month, all rather off-putting sums for the 普通の／平均（する） Joe anywhere.
Costs are much lower here ? around £150 every four weeks ? but America is the biggest healthcare market in the world and the fat jabs remain out of reach for millions. The problem is 特に 激烈な／緊急の because most 患者s rely on 保険会社s to 支払う／賃金 for their 医療の 治療s and many 辞退する to cover the cost of 負わせる loss 麻薬s.
Over time, the hope is that 供給（する）s will 増加する and costs 落ちる. Both companies are taking steps to 増加する 製造業の capacity and 計画（する）s are 進行中で to make the jabs more affordable.
However, 研究員s from Yale University and King's College Hospital in London 示唆する that the 麻薬s can be made for いっそう少なく than £1 a week, piling 圧力 on both 操作者s to bring 負かす／撃墜する prices.
Novo Nordisk, a Danish 麻薬s group, created Ozempic, 初めは designed to 扱う／治療する 糖尿病 but now 広範囲にわたって used by 食餌療法している人s, too
The Chinese pill 製造者 and risky biotech 会社／堅いs?
圧力 is also likely to 開始する as other 麻薬 会社／堅いs delve into this market. UK-名簿（に載せる）／表（にあげる）d AstraZeneca has licensed an 実験の anti-obesity pill under 開発 by Eccogene, a Chinese biotech 会社／堅い.
AstraZeneca boss Pascal Soriot made an upfront 支払い（額） of $185 million (£146 million) for the licence but could 支払う／賃金 up to $2 billion (£1.58 billion), if the new 麻薬 証明するs successful.
The sums を強調する how much excitement surrounds the 負わせる loss market. Eccogene's 製品 has many 臨床の and regulatory 障害物s to 打ち勝つ before Soriot can even think about 商業の sales but support is building because people prefer pills to jabs.
With this in mind, Novo Nordisk and Eli Lilly are looking at oral 使用／適用s for their 麻薬s, while a host of other 会社／堅いs in the 部門 are 押し進めるing ahead with 裁判，公判s for competing 製品s.?
The field is 公正に／かなり （人が）群がるd, 含むing Nasdaq-名簿（に載せる）／表（にあげる）d 会社／堅いs Viking 治療力のあるs, Amgen and Terns 製薬のs and German drugmaker Boehringer Ingelheim.
投資家s looking for a way into this market may choose to stick with Novo Nordisk and Eli Lilly, as they are profitable, 支払う／賃金 （株主への）配当s and their 麻薬s are already on sale. The 旅行 ahead may be bumpy, however.?
Hargreaves Lansdown's Susannah Streeter explains: 'We're excited about Novo Nordisk's long-称する，呼ぶ／期間／用語 可能性のある but the 見込み of ups and 負かす／撃墜するs remains elevated.'
Those looking for a smoother ride might consider healthcare-焦点（を合わせる）d 投資 信用s, such as 世界的な Healthcare 信用, whose 最高の，を越す ten holdings 含む Novo, Eli Lilly and AstraZeneca, or Polar 全世界の Healthcare, which has 投資するd more than 8 per cent of its cash in Eli Lilly.
The higher 危険 UK small-cap 選択...?
Adventurers might be tempted by something 完全に different, 目的（とする）-名簿（に載せる）／表（にあげる）d 水晶 Amber, which 投資するs in underperforming 商売／仕事s and tries to change them for the better.
Having worked with 非常に／多数の 会社／堅いs, 水晶 Amber is now 焦点（を合わせる）d on two, banknote printer De La Rue and Morphic 医療の, a US outfit which has developed a gut liner to help the 本気で overweight to shed 続けざまに猛撃するs.
挿入するd under anaesthetic or sedation, the sleeve-like 装置 減ずるs hunger and 使用者s appear to be able to keep their 負わせる off even after it is 除去するd.
Jeremy Clarkson, 62, （人命などを）奪う，主張するd Ozempic had a 'tremendous' 影響 on his 負わせる
Morphic is 推定する／予想するd to 安全な・保証する UK and European 是認 for its 道具 this summer, a pivotal moment which could have a 劇の 影響 on the company's value.
While 注射s and pills are 明確に いっそう少なく invasive than Morphic's gut liner, kn own as RESET, the sleeve may work better for some 患者s and could save the NHS millions of 続けざまに猛撃するs, compared to Novo Nordisk 麻薬s.
利益／興味 in Morphic is growing so a sale of the entire 商売／仕事 may 井戸／弁護士席 be on the cards.?
With 水晶 Amber owning more than 80 per cent of the 株 in the company and 負わせる loss valuations riding high, this could 配達する juicy pickings.?
水晶 boss Richard Bernstein is also hoping for 早期に 伸び（る）s from De La Rue, where it has a 17 per cent 火刑／賭ける, valued at £32 million. De La Rue 株 are just 94p today but Bernstein has agitated for change and a review is 進行中で, the results of which will be 明らかにする／漏らすd at the end of this month.
水晶 Amber 株 are just 78p and the entire company is valued at いっそう少なく than £60 million so the 在庫／株 could 申し込む／申し出 a cheap way into the 負わせる loss market.
Compare the best DIY 投資するing 壇・綱領・公約s and 在庫／株s & 株 Isas
投資するing online is simple, cheap and can be done from your computer, tablet or phone at a time and place that 控訴s you.
When it comes to choosing a DIY 投資するing 壇・綱領・公約, 在庫／株s & 株 Isa or a general 投資するing account, the 範囲 of 選択s might seem 圧倒的な.?
Every provider has a わずかに different 申し込む／申し出ing, 非難する more or いっそう少なく for 貿易（する）ing or 持つ／拘留するing 株 and giving 接近 to a different 範囲 of 在庫／株s, 基金s and 投資 信用s.?
When 重さを計るing up the 権利 one for you, it's important to to look at the service that it 申し込む／申し出s, along with 行政 告発（する），告訴（する）／料金s and 取引，協定ing 料金s, 加える any other extra costs.
To help you compare the best 投資 accounts, we've crunched the facts and pulled together a 包括的な guide to choosing the best and cheapest 投資するing account for you.?
We 最高潮の場面 the main players in the （米）棚上げする／（英）提議する below but would advise doing your own 研究 and considering the points in our 十分な guide linked here.
>> This is Money's 十分な guide to the best 投資するing 壇・綱領・公約s and Isas?
壇・綱領・公約s featured below are 独立して selected by This is Money’s specialist 新聞記者／雑誌記者s. If you open an account using links which have an asterisk, This is Money will earn an (v)提携させる(n)支部，加入者 （売買）手数料，委託（する）／委員会／権限. We do not 許す this to 影響する／感情 our 編集（者）の independence.?
| Admin 告発（する），告訴（する）／料金 | 告発（する），告訴（する）／料金s 公式文書，認めるs | 基金 取引，協定ing | 基準 株, 信用, ETF 取引，協定ing | 正規の／正選手 投資するing | （株主への）配当 reinvestment | ||
|---|---|---|---|---|---|---|---|
| AJ Bell*? | 0.25%? | Max £3.50 per month for 株, 信用s, ETFs.? | £1.50 | £5? | £1.50 | £1.50 per 取引，協定? | More 詳細（に述べる）s |
| Bestinvest* | 0.40% (0.2% for ready made 大臣の地位s) | Account 料金 削減（する） to 0.2% for ready made 投資s | 解放する／自由な | £4.95 | 解放する／自由な for 基金s? | 解放する／自由な for income 基金s | More 詳細（に述べる）s |
| Charles Stanley Direct* | 0.35%? | No 壇・綱領・公約 料金 on 株 if a 貿易（する） in that month and 年次の max of £240 | 解放する／自由な | £11.50 | n/a | n/a | More 詳細（に述べる）s |
| Fidelity* | 0.35% on 基金s | £7.50 per month up to £25,000 or 0.35% with 正規の／正選手 貯金 計画（する）.? | 解放する／自由な | £7.50 | 解放する／自由な 基金s £1.50 株, 信用s ETFs | £1.50 | More 詳細（に述べる）s |
| Hargreaves Lansdown* | 0.45% | Capped at £45 for 株, 信用s, ETFs | 解放する／自由な | £11.95 | £1.50 | 1% (£1 min, £10 max) | More 詳細（に述べる）s |
| Interactive 投資家*? | £4.99 per month under £50k, £11.99 above, £10 extra for Sipp | 自由貿易 価値（がある） £3.99 per month (does not 適用する to £4.99 計画（する）) | £3.99 | £3.99 | 解放する／自由な | £0.99 | More 詳細（に述べる）s |
| iWeb | £100 one-off 料金 (waived until July 2024) | £5 | £5 | n/a | 2%, max £5 | More 詳細（に述べる）s | |
| ?Accounts that have some 限界s but attractive 申し込む／申し出s | ? | ? | |||||
| Etoro*??No 投資 基金s or Sipp | 解放する／自由な | 投資 account 申し込む／申し出s 在庫／株s and ETFs. Beware high 危険 CFDs. | Not 利用できる? | 解放する／自由な? | n/a? | n/a? | More 詳細（に述べる）s? |
| 貿易（する）ing 212*? | 解放する／自由な? | 投資 account 申し込む／申し出s 在庫／株s and ETFs. Beware high 危険 CFDs.? | Not 利用できる? | 解放する／自由な? | n/a? | 解放する／自由な? | More 詳細（に述べる）s? |
| Freetrade* No 投資 基金s | ?Basic account 解放する／自由な,? 基準 with Isa £4.99, 加える £9.99 | Freetrade 加える with more 投資s and Sipp is £9.99/month inc. Isa 料金 | No 基金s? | 解放する／自由な? | n/a? | n/a? | More 詳細（に述べる）s? |
| 先導??Only 先導's own 製品s | 0.15%? | Only 先導 基金s | 解放する／自由な? | 解放する／自由な only 先導 ETFs? | 解放する／自由な? | n/a? | More 詳細（に述べる）s? |
| (Source: ThisisMoney.co.uk May 2024. Admin % 告発（する），告訴（する）／料金 may be 徴収するd 月毎の or 年４回の | |||||||
?
